Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Delivery

Novo, Dicerna to develop liver disease drugs

by Lisa M. Jarvis
November 23, 2019 | A version of this story appeared in Volume 97, Issue 46

 

Novo Nordisk will pay Dicerna Pharmaceuticals $225 million, which includes up-front fees and an equity investment, as part of a broad collaboration to develop RNAi-based therapies targeting liver-related diseases. Dicerna’s technology platform hinges on using a substrate for an enzyme called Dicer to deliver a drug into cells, where it can turn off a specific gene. The companies will work on more than 30 liver cell targets, including ones implicated in nonalcoholic steatohepatitis, type 2 diabetes, and obesity.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.